Amplify Treatments, Testing and Advancements ETF
Data updated: 2024-08-27
C000245561 — Amplify Treatments, Testing and Advancements ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Materials Equity · $9.24M AUM · 0.68% expense ratio. From SEC regulatory filings.
C000245561 Fund Overview
Amplify Treatments, Testing and Advancements ETF is a US mutual fund managed by Amplify ETF Trust, categorised as United States Materials Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Amplify ETF Trust
- Category: United States Materials Equity
- Assets under management: $9.24M
- SEC CIK: 0001633061
- SEC series ID: S000082275
- Share class ID: C000245561
C000245561 Holdings
Top 10 holdings of Amplify Treatments, Testing and Advancements ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Alnylam Pharmaceuticals Inc | 10.34% |
| First American Government Obli | 9.96% |
| Labcorp Holdings Inc | 6.52% |
| Quest Diagnostics Inc | 6.10% |
| BioNTech SE | 5.02% |
| Moderna Inc | 4.88% |
| Vaxcyte Inc | 4.41% |
| ImmunityBio Inc | 4.40% |
| Bio-Rad Laboratories Inc | 4.00% |
| Zai Lab Ltd | 3.86% |
C000245561 Portfolio Allocation
Asset-class allocation of Amplify Treatments, Testing and Advancements ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 98.9% |
| Cash & Equivalents | 11.2% |
C000245561 Costs and Fees
C000245561 costs about $68 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.68%
- Gross expense ratio: 0.68%
- Portfolio turnover: 55%
C000245561 Cashflows
Over the 12 months to 2024-06, Amplify Treatments, Testing and Advancements ETF had net outflows of $2.76M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2024-06 | −$1.01M |
| 2024-05 | $0 |
| 2024-04 | −$840.59K |
| 2024-03 | $0 |
| 2024-02 | −$907.67K |
| 2024-01 | $0 |
C000245561 Debt Constituents
No individual debt constituents are reported in Amplify Treatments, Testing and Advancements ETF's latest SEC N-PORT filing.
C000245561 Prospectus and SEC Filings
Official Amplify Treatments, Testing and Advancements ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Materials Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.